Lanoxin (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, leading to increased intracellular calcium. This enhances the strength of each heartbeat (positive inotropic effect) and slows conduction through the AV node, which helps regulate heart rhythm in atrial arrhythmias.

The specific dose of Lanoxin is individualized by the prescribing clinician based on factors such as the patient’s weight, renal function, electrolyte status, and therapeutic response. Only a qualified healthcare professional should determine the appropriate regimen.

Lanoxin is classified as Pregnancy Category C, indicating that risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding, so a clinician should evaluate the risk‑benefit ratio before use.

To place an order, submit an enquiry on the Lanoxin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Lanoxin belongs to the cardiac glycoside class, offering a unique positive inotropic effect not provided by most modern heart‑failure drugs such as ACE inhibitors or beta‑blockers. While it can improve symptoms in selected patients, its narrow therapeutic window and potential for toxicity mean it is usually reserved for those who remain symptomatic despite standard therapy.

Lanoxin must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Lanoxin is supplied as an injectable solution for intravenous use. Administration is performed by a qualified healthcare professional, typically as a slow IV push or infusion, following the dosing instructions provided by the prescriber and institutional protocols.

The most serious risks include life‑threatening cardiac arrhythmias such as ventricular tachycardia, severe bradycardia, or complete heart block, as well as digoxin toxicity manifested by gastrointestinal symptoms, visual disturbances, and electrolyte imbalances, particularly hyperkalemia.

Lanoxin is contraindicated in patients with known ventricular arrhythmias, advanced atrioventricular block without a pacemaker, and those with severe renal impairment that cannot be adequately monitored. It should also be avoided in individuals with hypersensitivity to digoxin or any component of the formulation.